JAK inhibitor sequencing and transplant timing in myelofibrosis discussed at 2026 conference

Dr. Andrew Kuykendall of Moffitt Cancer Center explained how doctors decide the order of JAK inhibitor therapies and when to consider allogeneic stem cell transplant for myelofibrosis patients.

At the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma meeting in May 2026, he highlighted that transplant remains the only potentially curative option but carries high risk, making timing decisions critical.

He noted that the biggest unanswered question is the optimal point to refer patients for transplant, and that ongoing debate continues about how best to integrate JAK inhibitors with transplant strategies.